August 27, 2017
PRA Health Sciences Announces Partnership With Jumo Health
Image of children

RALEIGH, N.C. (June 19, 2017)

As part of its new Center for Pediatric Clinical Development initiative, PRA Health Sciences is pleased to announce its partnership with Jumo. Jumo is an award-winning provider of educational health care information and resources for children, families, and caregivers.

“We are excited about this partnership,” said Mark Sorrentino, Vice President, The Center for Pediatric Clinical Development. “When it comes to pediatric clinical trials, we know that patients and caregivers are fearful and there is often a lack of understanding of what to expect. Jumo’s novel materials aid in the education and engagement of these trials.”

PRA’s new Center for Pediatric Clinical Development which was announced earlier this year is looking to bring innovation to pediatric clinical trial design and implementation and to facilitate patient recruitment. “We look forward to collaborating with PRA and finding new and innovative ways to assist young patients and their families and to help them remain engaged and motivated in clinical trials,” said Kate Hersov, Founder,

A provider of consulting services as well as experienced technical and operational services, The Center for Pediatric Clinical Development team connects PRA’s pediatric expertise across functional areas into a single global resource to support all aspects of client needs related to pediatric product development.

About PRA Health Sciences

PRA (NASDAQ: PRAH) is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,300 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit

Jumo Health develops age-appropriate, culturally relevant, and relatable educational resources for patients and caregivers. We have experience serving diverse populations, covering more than 160 health topics across 80+ countries in 120+ languages. Our various digital, video, and print offerings use highly visual elements and research-backed health literacy strategies to ensure that everyone can understand and act upon complex medical information. We do this through familiar mediums – from comic books and animation, to virtual reality experiences and authentic documentary-style patient stories – all customized based on audience. Jumo Health collaborates globally with more than 180 advocacy groups and community organizations to promote access and to ensure unique patient experiences are accurately represented.

Media contact

For more information about Jumo Health or this article, contact Dani Himelright by calling +1 (614) 284-6804 or emailing

It looks like you're using an outdated browser. Please upgrade your browser for the best experience.